Video

Dr. Olopade on Moving the Needle Forward in Preventive Oncology and Genetics

Olufunmilayo I. Olopade, MD, FACP, discusses the need to focus efforts in preventive oncology and genetics.

Olufunmilayo Falusi Olopade, MD, FACP, director of the Center for Clinical Cancer Genetics, director of the Center for Global Health, associate dean for Global Health, and the Walter L. Palmer Distinguished Service Professor of Medicine and Human Genetics at the University of Chicago Medicine, discusses the need to focus efforts in preventive oncology and genetics.

It was an honor to be recognized as a Giant of Cancer Care® for Prevention and Genetics, says Olopade, as she has dedicated the majority of her career to bringing genetics into clinical oncology care. The oncology community has come to embrace the fact that prevention oncology is an important area where efforts should be focused, Olapade adds.

Olopade accepted her award on behalf of her colleagues who inspired her to find ways to bring genetics to the average community oncology practice; this has helped to move the needle forward over the past 25 years, she concludes.

Related Videos
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.